Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer

202032 citationsJournal Articlegold Open Access

Authors

Eva Crespo-Rodriguez · Institute of Cancer Research

Katharina Bergerhoff · Institute of Cancer Research

Galabina Bozhanova · Institute of Cancer Research

Shane Foo · Institute of Cancer Research

Emmanuel C. Patin · Institute of Cancer Research

Harriet Whittock · Institute of Cancer Research

Richard Buus

Abstract

The combination of oHSV and BRAF inhibition significantly improved survival in a mouse model of ATC by enhancing immune-mediated antitumor effects, and triple combination therapies, including either PD-1 or CTLA-4 blockade, further improved therapy.

Topics & Keywords

interferon and immune responses Virus-based gene therapy research Cancer Research and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal for ImmunoTherapy of Cancer

Volume 8, Issue 2, pp. e000698-e000698

DOI: 10.1136/jitc-2020-000698

Field-Weighted Citation Impact: 0.97